Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news
Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news
Does an Arthritis Drug Help Patients Battling Severe COVID? It Depends on the Study
WEDNESDAY, March 3, 2021 -- Two new studies suggest that the jury is still out on whether the arthritis drug tocilizumab helps those with severe COVID-19.
Both reports were published recently in the New England Journal of Medicine. The first, from... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 3, 2021 Category: General Medicine Source Type: news
IL - 6 Receptor Antagonists Benefit Critically Ill With COVID - 19
Improved outcomes, including more organ support - free days, reduced mortality, seen with tocilizumab, sarilumab (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 2, 2021 Category: Respiratory Medicine Tags: Infections, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news
IL-6 Receptor Antagonists Benefit Critically Ill With COVID-19
TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ support in the intensive care unit (ICU), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 2, 2021 Category: Pharmaceuticals Source Type: news
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia, New England Journal of Medicine
This placebo-controlled Phase III study of tocilizumab in patients hospitalised with severe Covid-19 pneumonia found no improvement in clinical status (primary endpoint; between-group difference -1.0; 95% CI -2.5 to 0; p=0.31) or mortality (19.7% v 19.4%; p=0.94) at day 28. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 1, 2021 Category: Consumer Health News Source Type: news
COVID-19 rapid evidence summary: Tocilizumab for COVID-19, NICE (updated 24th February 2021)
Evidence summary updated at the request of NHS England because new evidence was identified: prepublication study results from the nationally prioritised platform study (Horby et al. 2021; the RECOVERY study), and a published randomised controlled trial (Veiga et al. 2021). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 1, 2021 Category: Consumer Health News Source Type: news
Repurposed arthritis drug did not significantly improve severe COVID-19 pneumonia
(University of California - San Diego) A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 1, 2021 Category: Infectious Diseases Source Type: news
Tocilizumab May Improve Lung Function in Early Systemic Sclerosis Tocilizumab May Improve Lung Function in Early Systemic Sclerosis
Treatment with tocilizumab could stabilize or improve lung function in people with early interstitial lung disease associated with systemic sclerosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
UK Interim Clinical Commissioning Policy for tocilizumab has been updated to cover a wider group of hospitalised COVID-19 positive patients, DHSC
NHS trusts/health boards are recommended to consider prescribing single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following announcement of findings of RECOVERY trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 19, 2021 Category: Consumer Health News Source Type: news
Coronavirus update: Tocilizumab is a life-saving treatment for severely ill patients
CORONAVIRUS is being attacked from all angles, with game-changing treatments driving down the fatality rate in hospitals. In a press briefing on Monday, the government's Chief Medical Officer suggests arthritis drug tocilizumab strengthens the fight against COVID-19. (Source: Daily Express - Health)
Source: Daily Express - Health - February 15, 2021 Category: Consumer Health News Source Type: news
COVID-19 rapid guideline: critical care in adults [NG159], NICE (updated 12th February 2021)
Updated On 12 February 2021, we added advice to follow NHS England ' s interim clinical commissioning policies on tocilizumab and sarilumab for treating critically ill patients with COVID-19 pneumonia. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 12, 2021 Category: Consumer Health News Source Type: news
New coronavirus drug: What is life-saving drug Tocilizumab?
A DRUG normally used for arthritis has provided hope for coronavirus patients in hospital. What is life-saving drug Tocilizumab? (Source: Daily Express - Health)
Source: Daily Express - Health - February 11, 2021 Category: Consumer Health News Source Type: news
Roche arthritis drug cuts deaths in hospitalized COVID-19 patients, study suggests
Roche's arthritis drug tocilizumab cuts the risk of death among patients hospitalized with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, a large clinical trial suggests. (Source: CBC | Health)
Source: CBC | Health - February 11, 2021 Category: Consumer Health News Tags: News/Health Source Type: news
Roche's Tocilizumab Cuts Deaths in Hospitalized COVID-19 Patients: Study Roche's Tocilizumab Cuts Deaths in Hospitalized COVID-19 Patients: Study
Roche ' s arthritis drug tocilizumab cuts the risk of death among patients hospitalized with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, results of a large trial showed on Thursday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
